One good example is that abnormal activation of Smoothened (Smo), an atypical G protein-coupled receptor (GPCR), results in basal cell carcinoma (BCC) and medulloblastoma1, 2, therefore Smo has been an attractive therapeutic target, exemplified by the newly FDA approved drugs6. The gene discussed is SMO; the disease is basal cell carcinoma.